Comparing the current results to its competitors, Lipella Pharmaceuticals Inc reported Revenue decrease in the 3 quarter 2025 year on year by 0 %, despite the revenue increase by the most of its competitors of 806.75 %, recorded in the same quarter.
Lipella Pharmaceuticals Inc 's Comment on Competition and Industry Peers
The company operates in the competitive biotechnology and pharmaceutical industries. It is not aware of other clinical programs targeting new products for HC, OLP, or GVHD. Several pharmaceutical companies are developing intravesical technologies for indications such as transitional cell carcinoma, a superficial, non-muscle invasive form of bladder cancer. These companies and new entrants may compete with the company's products LP-10, LP-310, and other products developed using novel delivery technologies. The company plans to rely on market data exclusivity from FDA orphan drug designation for LP-10, as well as issued patents in the U.S., Australia, Canada, and Europe, to maintain competitive advantages.
April 22, 2025
Lipella Pharmaceuticals Advances in Oral Lichen Planus Treatment and Bladder Imaging Technology Lipella Pharmaceuticals, a pioneering biopharmaceutical company, has announced significant advancements in its clinical trials and imaging techniques, positioning itself at the forefront of medical innovation. Notably, the company has reported positive results from the second cohort of its Phase 2a trial investigating LP-310 for the treatment of oral lichen planus, a chronic inflammatory condition characterized by painful ulcers in the mucous membranes of the mouth. This promising development coincides with the introduction of a cutting-edge bladder imaging technique presented at the ICICJ Conference, showcasing L...
July 29, 2024
Lipella Pharmaceuticals has officially commenced its Phase 2a clinical trial for LP-310, a potential treatment aimed at alleviating Oral Lichen Planus (OLP). This development marks a significant step forward in the quest to manage this chronic inflammatory condition, which affects the mucous membranes within the mouth. Oral Lichen Planus is characterized by painful lesions and can severely impact a patient s quality of life. Current treatment options are limited, highlighting the need for effective therapies that target the underlying pathophysiology of the condition. LP-310 is designed to address these needs, and this Phase 2a trial aims to assess both the safety and efficacy of the drug in patients suffe...
May 29, 2024
Groundbreaking Developments at Lipella Pharmaceuticals: Upcoming ASCO Presentation and FDA Type C Meeting Lipella Pharmaceuticals, a clinical-stage biotechnology company dedicated to the development of innovative treatments for urologic diseases, has announced the publication of an abstract at the prestigious 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. This announcement marks a significant milestone for the company, reflecting its continued commitment to pioneering solutions that address unmet medical needs. Selection at ASCO 2024 Annual MeetingThe abstract chosen for the ASCO 2024 Annual Meeting showcases Lipella Pharmaceuticals cutting-edge research and development efforts. This an...
April 5, 2024
In a recent announcement by Lipella Pharmaceuticals, the esteemed biopharmaceutical company highlighted plans to publish an abstract detailing substantial preclinical support for its new product candidate. The abstract is slated to go public on the prestigious platform of the American Society of Clinical Oncology (ASCO) Annual Meeting, 2024. This cutting-edge revelation embodies the company s formidable commitment to nurturing innovation with the potential to revolutionize the pharmaceutical landscape.Pioneering a wave of strategic innovation, Lipella Pharmaceuticals is harnessing scientific expertise to deliver a groundbreaking new candidate. The unveiling of compelling preclinical evidence supporting the e...
Publicly Traded Peers of Lipella Pharmaceuticals Inc
Agios Pharmaceuticals Inc Share Performance
+19.94%
This Quarter
Agios Pharmaceuticals Inc
Profile
Agios Pharmaceuticals Inc is a biopharmaceutical company that focuses on researching and developing innovative therapies for treating genetic diseases and cancer.
Collegium Pharmaceutical Inc's business model revolves around the development and commercialization of innovative products specifically designed to address the limitations of existing treatment options in pain management. They focus on developing extended-release formulations that offer abuse-deterrent properties to enhance patient safety and combat prescription drug abuse. By leveraging strategic partnerships, they aim to bring their products to market efficiently and effectively.
Lantern Pharma Inc's business model focuses on leveraging artificial intelligence and machine learning to identify and repurpose existing drugs for the treatment of various diseases.
Medpace Holdings Inc is a contract research organization (CRO) that provides various services in the clinical research and development of drugs and medical devices.
Mallinckrodt Plc's business model revolves around acquiring and developing branded pharmaceutical products, as well as manufacturing and distributing generic and specialty pharmaceuticals. They aim to address unmet medical needs and improve patient lives through their diverse portfolio of drugs.
Sources:
Lipella Pharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Lipella Pharmaceuticals Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
